The Human Biological Sampling and Immunocytometry core will provide essential clinical and immunological support for both projects in this proposal. The core encompasses personnel with appropriate technical expertise to accomplish the proposed studies, and the resources/facilities with which to do so. Vital to the entire program project is obtaining human samples for experimentation, which is the first of three functions of the core. Along with participant recruitment, and obtaining specimens, the Subject Recruitment and Biological Sampling component of the core will oversee efficient distribution of cells to the appropriate laboratories. Two additional components of the core, the Cellular Processing component and the Flow Cytometry component, are aimed at preparing samples for proposed experiments and in some cases performing data acquisition and analysis. Each of these two components will be involved in setting up initial BAL cell and airway epithelial cell cultures, as well as data acquisition and analysis for certain aspects of both projects.
The specific aims for the proposed core are as follows:
Aim 1 : Subject Recruitment and Biological Sampling. This component will help to recruit healthy controls and asthmatics of varying severity and obtain biological specimens. In addition, the core will oversee efficient distribution of cells to the appropriate laboratories.
Aim 2 : Cellular Processing. This component is aimed at preparing samples for the proposed experiments in the two projects and Core C.
Aim 3 : Flow Cytometry. In this component, the core will work with investigators to provide immunophenotyping of cells via staining with labeled antibodies. In addition, the core will assist investigators with performance of high-yield, high-purity cell sorts to provide material from human blood and BAL fluid for further experimentation.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program Projects (P01)
Project #
5P01AI106684-02
Application #
9067284
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
2016-06-01
Budget End
2017-05-31
Support Year
2
Fiscal Year
2016
Total Cost
Indirect Cost
Name
University of Pittsburgh
Department
Type
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Oriss, Timothy B; Raundhal, Mahesh; Morse, Christina et al. (2017) IRF5 distinguishes severe asthma in humans and drives Th1 phenotype and airway hyperreactivity in mice. JCI Insight 2:
Das, Sudipta; Raundhal, Mahesh; Chen, Jie et al. (2017) Respiratory syncytial virus infection of newborn CX3CR1-deficent mice induces a pathogenic pulmonary innate immune response. JCI Insight 2:
Gauthier, Marc; Chakraborty, Krishnendu; Oriss, Timothy B et al. (2017) Severe asthma in humans and mouse model suggests a CXCL10 signature underlies corticosteroid-resistant Th1 bias. JCI Insight 2:
Modena, Brian D; Bleecker, Eugene R; Busse, William W et al. (2017) Gene Expression Correlated with Severe Asthma Characteristics Reveals Heterogeneous Mechanisms of Severe Disease. Am J Respir Crit Care Med 195:1449-1463
Ray, Anuradha; Kolls, Jay K (2017) Neutrophilic Inflammation in Asthma and Association with Disease Severity. Trends Immunol 38:942-954
Wenzel, Sally E; Tyurina, Yulia Y; Zhao, Jinming et al. (2017) PEBP1 Wardens Ferroptosis by Enabling Lipoxygenase Generation of Lipid Death Signals. Cell 171:628-641.e26
Trejo Bittar, Humberto E; Doberer, Daniel; Mehrad, Mitra et al. (2017) Histologic Findings of Severe/Therapy-Resistant Asthma From Video-assisted Thoracoscopic Surgery Biopsies. Am J Surg Pathol 41:182-188
Eddens, Taylor; Campfield, Brian T; Serody, Katelin et al. (2016) A Novel CD4+ T Cell-Dependent Murine Model of Pneumocystis-driven Asthma-like Pathology. Am J Respir Crit Care Med 194:807-820
Ray, Anuradha; Raundhal, Mahesh; Oriss, Timothy B et al. (2016) Current concepts of severe asthma. J Clin Invest 126:2394-403
Chen, Kong; Campfield, Brian T; Wenzel, Sally E et al. (2016) Antiinflammatory effects of bromodomain and extraterminal domain inhibition in cystic fibrosis lung inflammation. JCI Insight 1:

Showing the most recent 10 out of 16 publications